Clinical trials: Cancer, Hepatocellular
Colorectal Adenocarcinoma, Gastric Adenocarcinoma
Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors
This is a multi-center, open label, repeat dose, Phase 1 study consisting of a Dose Escalation Phase and a Dose Expansion Phase to evaluate safety, pharmacokinetics, and clinical activity.
- Conditions
- Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Bile Duct Carcinoma
- Trial name
- NCT03507998
- Testing
- CGX1321
- Where
- 2 sites in China
- Volunteers
- 39 people
- Sponsor
- Curegenix Inc.
HCC - Hepatocellular Carcinoma
Real-world Insight Into Systemic Therapies for HCC: Single-center Study
Real-world data from a single-center experience evaluating patients with hepatocellular carcinoma (HCC) receiving systemic therapies
- Trial name
- HCC (NCT07814014)
- Where
- Egypt
- Volunteers
- 1,000 people
- Sponsor
- Mansoura University
Positron-Emission Tomography, Carcinoma, Hepatocellular
Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma
The aim of this study is to make up for this gap by performing a dynamic scan of 18F-FDG PET/CT on newly diagnosed patients with liver cancer. The lesions and/or metastases are performed for biopsy.
- Trial name
- NCT03636607
- Testing
- PET/CT dynamic scan
- Where
- China
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Uveal Melanoma, Cutaneous Melanoma
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1.
- Conditions
- Uveal Melanoma, Cutaneous Melanoma, BAP1 Gene Mutation, Renal Cell Carcinoma
- Trial name
- NCT04792463
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Mohamed Abdel-Rahman
Hepatocellular Carcinoma
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
The main purpose of this study is to compare the overall survival (OS) of nivolumab plus ipilimumab versus standard of care (SOC) (sorafenib or lenvatinib) in all randomized participants with advanced hepatocellular carcinoma…
- Trial name
- CheckMate 9DW (NCT04039607)
- Testing
- Nivolumab, Ipilimumab, Sorafenib
- Where
- 210 sites in United States, Argentina and 24 more
- Volunteers
- 732 people
- Sponsor
- Bristol-Myers Squibb
Adult Primary Hepatocellular Carcinoma, Localized Unresectable Adult Primary Liver Cancer
Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
This phase II trial is to see if bevacizumab works in treating patients who have unresectable nonmetastatic liver cancer that has not spread to the main portal vein.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00055692
- Testing
- bevacizumab
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma
The purpose of this study is to determine whether patients with hepatocellular carcinoma who receive either E7050 administered with Sorafenib or Sorafenib alone experience greater benefit (cancer responds to treatment) when E7050…
- Trial name
- NCT01271504
- Testing
- Sorafenib
- Where
- 24 sites in United States, Belgium and 4 more
- Volunteers
- 102 people
- Sponsor
- Eisai Inc.
Hepatocellular Carcinoma
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
The TERTIO trial will propose to determine the clinical interest and immunological efficacy of a treatment combining the CD4 helper T-inducer cancer anti-telomerase vaccine (UCPVax) with anti-PD-L1 therapy (atezolizumab) and…
- Trial name
- TERTIO (NCT05528952)
- Testing
- Atezolizumab, Bevacizumab, UCPVax
- Where
- 14 sites in France
- Volunteers
- 105 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Liver Tumors Not Resectable in One Surgical Procedure
ALLPS VERSUS PVO Randomized Controlled Trial
This randomized phase II trial compares how well associating liver partition with portal vein ligation for staged hepatectomy (ALPPS) or portal vein occlusion (PVO) works in treating patients with liver cancer.
- Trial name
- ALPPS (NCT01775267)
- Testing
- Associating liver partition and portal vein ligation for staged hepatectomy, Portal vein embolization or ligation
- Where
- 3 sites in United States, Argentina and 1 more
- Volunteers
- 7 people
- Sponsor
- University of Zurich
Hepatocellular Carcinoma
Hepatic Artery Infusion Chemotherapy for Unresectable Hepatocelluar Carcinoma Who Failed to Systemic Therapy
There are limited treatment options for patients with unresectable hepatocellular carcinoma (HCC) who failed to the combination therapy with targeted agents plus anti-PD-1/PD-L1.
- Trial name
- NCT04994236
- Testing
- Hepatic artery infusion chemotherapy with FOLFOX regimens (oxaliplatin, fluorouracil, and leucovorin)
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Hui-Chuan Sun
Hepatocellular Carcinoma
Simo Decoction and Gum Chewing for Bowel Activity
Abdominal surgery, including hepatic resection for hepatocellular carcinoma (HCC), is inevitably followed by an episode of gastrointestinal hypomotility.
- Trial name
- SD/GC-HCC (NCT02438436)
- Testing
- simo decoction, gum chewing
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma
Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer
The goal of this clinical trial is to evaluate the efficacy and safety of cardonilizumab injection combined with TKI in second-line treatment of advanced hepatocellular carcinoma.
- Trial name
- NCT06363006
- Testing
- TKI+Cardunilimab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Hepatocellular Carcinoma, Liver Cancer
SU011248 in Advanced Hepatocellular Carcinoma
The main purpose of this study is to begin to collect information and try to learn whether SU011248 works in treating patients with advanced liver cancer.
- Trial name
- NCT00361309
- Testing
- SU011248
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
Carcinoma, Hepatocellular
Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas
The purpose of the study is to evaluate the effects of Transcatheter Arterial Chemoembolization (TACE) with KMG microsphere in treating advance-stage Hepatocellular Carinoma(HCC).
- Trial name
- TACE-KMG (NCT01393093)
- Testing
- Therapeutic Chemoembolization
- Where
- China
- Volunteers
- 2,840 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Digestive Cancer, Metastatic Colorectal Cancer
TARGETed Therapy Drug MONITOring in DIGestive Oncology
Targeted therapy drug monitoring in digestive oncology: Dosage of plasma levels of various multikinase inhibitors (MKI) in patients treated for advanced digestive cancer (gastrointestinal stromal tumor (GIST), metastatic…
- Conditions
- Digestive Cancer, Metastatic Colorectal Cancer, Hepatocellular Carcinoma, GIST
- Trial name
- TARGETMONITO (NCT05443087)
- Testing
- Blood sampling to build population pharmacokinetics model
- Where
- 29 sites in France
- Volunteers
- 330 people
- Sponsor
- UNICANCER
Hepatocellular Carcinoma, Cholangiocarcinoma
Deep Liver Phenotyping and Immunology Study
Hepatocellular carcinoma (HCC) and cholangiocarcinoma are the two most common causes of primary liver cancer and HCC is the second highest cause of cancer death worldwide.
- Trial name
- DELPHI (NCT04946773)
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- University of Oxford
Hepatocellular Carcinoma
Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Sorafenib is the standard therapy for advanced liver cancer but often shows dose-limiting toxicities with the need to reduce the applied dose of the compound.
- Trial name
- NCT01335074
- Testing
- Temsirolimus + Sorafenib
- Where
- Germany
- Sponsor
- Philipps University Marburg
Hepatocellular Carcinoma (HCC)
Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors
This is a single-center, single-arm, prospective trial to explore the efficacy and safety of Icaritin Soft Capsules combined with postoperative adjuvant hepatic arterial infusion chemotherapy(HAIC) with Modified Folinic acid…
- Trial name
- NCT07337460
- Testing
- Icaritin Soft Capsules and mFOLFOX ：Oxaliplatin,leucovorin calcium,5-fluorouracil
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Northern Jiangsu People's Hospital
Hepatocellular Carcinoma
Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
The goal of this Phase 1b clinical trial is to evaluate the safety and efficacy of cryoablation and hepatic arterial administration of SD-101 in participants with advanced hepatocellular carcinoma.
- Trial name
- NCT06710223
- Testing
- SD-101, Cryotherapy, Tremelimumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Diego
Liver Neoplasms, Ablation Techniques
Standardization of Multi-modal Tumor Ablation Therapy System
This study will document for the safety and efficacy of image guided multi-mode precision ablation system (the combination of cryoablation and radiofrequency ablation) for the treatment of liver malignant, as well as provide the…
- Conditions
- Liver Neoplasms, Ablation Techniques, Cryoablation, Safety
- Trial name
- SMTATS (NCT03223142)
- Testing
- Multi-modal Precision Ablation
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Zhongshan Hospital